Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS, Sun T, Zhuo C, D'Souza G, Lee SH, Lan NH, Chiang CH, Wilson D, Sun F, Iaconis J, Melnick D. Zhong NS, et al. Lancet Infect Dis. 2015 Feb;15(2):161-71. doi: 10.1016/S1473-3099(14)71018-7. Epub 2014 Dec 22. Lancet Infect Dis. 2015. PMID: 25539586 Clinical Trial.
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
Corey GR, Wilcox MH, Gonzalez J, Jandourek A, Wilson DJ, Friedland HD, Das S, Iaconis J, Dryden M. Corey GR, et al. Int J Antimicrob Agents. 2019 Jun;53(6):830-837. doi: 10.1016/j.ijantimicag.2019.01.016. Epub 2019 Feb 1. Int J Antimicrob Agents. 2019. PMID: 30716446 Free article.
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D. Taboada M, et al. Among authors: iaconis jp. J Antimicrob Chemother. 2016 Jun;71(6):1748-9. doi: 10.1093/jac/dkw136. Epub 2016 Apr 13. J Antimicrob Chemother. 2016. PMID: 27076104 No abstract available.
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.
Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J. Dryden M, et al. Among authors: iaconis jp. J Antimicrob Chemother. 2016 Dec;71(12):3575-3584. doi: 10.1093/jac/dkw333. Epub 2016 Sep 1. J Antimicrob Chemother. 2016. PMID: 27585969 Free PMC article. Clinical Trial.
In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF. Karlowsky JA, et al. Among authors: iaconis jp. J Antimicrob Chemother. 2016 Jan;71(1):162-9. doi: 10.1093/jac/dkv311. Epub 2015 Oct 26. J Antimicrob Chemother. 2016. PMID: 26503667
Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
Cristinacce A, Wright JG, Macpherson M, Iaconis J, Das S. Cristinacce A, et al. Diagn Microbiol Infect Dis. 2021 Apr;99(4):115292. doi: 10.1016/j.diagmicrobio.2020.115292. Epub 2020 Dec 13. Diagn Microbiol Infect Dis. 2021. PMID: 33360809 Free article.
24 results